Antifungal Activity of Eugenol and its Association with Nystatin on Candida albicans

Ingrid Carla Guedes da Silva, Hellen Bandeira de Pontes Santos, Yuri Wanderley Cavalcanti, Cassiano Francisco Weege Nonaka, Simone Alves de Sousa, Ricardo Dias de Castro


Objective: To evaluate the anti-Candida effect of eugenol and its antimicrobial interaction with nystatin. Material and Methods: The antimicrobial potential was assessed by microdilution technique (M27A3 reference method), by determining the minimum inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) against C. albicans (ATCC 90028). The possible action of eugenol on the fungal cell wall was evaluated with the assistance of the osmotic protector sorbitol (0.8 M). The antimicrobial interaction with nystatin was assessed through the checkerboard method. All tests were performed in triplicate. Results: All groups showed reductions in PI and GBI values and improvements in oral health knowledge, but IG1 and IG2 showed statistically significant differences in these variables compared to CG. Conclusion: The eugenol has antifungal activity against C. albicans and its mechanism of action is probably not related to damage to the fungal cell wall. Association between eugenol and nystatin was not found to be an advantageous possibility for growth inhibition of C. albican.


Eugenol; Nystatin; Drug synergism; Candida albicans.

Full Text:



Peleg AY, Hogan DA, Mylonakis E. Medically important bacterial-fungal interactions. Nat Rev Microbiol 2010; 8(5):340-9. doi: 10.1038/nrmicro2313.

Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74(4):323-31. doi: 10.1016/j.diagmicrobio.2012.10.003.

Gow NA, van de Veerdonk FL, Brown AJ, Netea MG. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 2011; 10(2):112-22. doi: 10.1038/nrmicro2711.

Williams DW, Jordan RP, Wei XQ, Alves CT, Wise MP, Wilson MJ, et al. Interactions of Candida albicans with host epithelial surfaces. J Oral Microbiol 2013; 5. doi: 10.3402/jom.v5i0.22434.

Sharifynia S, Badali H, Sharifi Sorkherizi M, Shidfar MR, Hadian A, Shahrokhi S, et al. In vitro antifungal susceptibility profiles of Candida albicans complex isolated from patients with respiratory infections. Acta Med Iran 2016; 54(6):376-81.

Dixon DM, Walsh TJ. Antifungal agents. In: Baron S (Ed.). Medical microbiology. edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 76.

Sheikh S, Gupta D, Pallagatti S, Singla I, Gupta R, Goel V. Role of topical drugs in treatment of oral mucosal diseases. A literature review. N Y State Dent J 2013; 79(6):58-64.

Jianhua W, Hai W. Antifungal susceptibility analysis of berberine, baicalin, eugenol and curcumin on Candida albicans. J Med Col PLA 2009; 24(3):142-7. doi: 10.1016/S1000-1948(09)60030-7.

Moges B, Bitew A, Shewaamare A. Spectrum and the in vitro antifungal susceptibility pattern of yeast isolates in Ethiopian HIV patients with oropharyngeal candidiasis. Int J Microbiol 2016; 2016:3037817. doi: 10.1155/2016/3037817.

de Paula SB, Bartelli TF, Di Raimo V, Santos JP, Morey AT, Bosini MA, et al. Effect of eugenol on cell surface hydrophobicity, adhesion, and biofilm of Candida tropicalis and Candida dubliniensis isolated from oral cavity of HIV-infected patients. Evid Based Complement Alternat Med 2014; 2014:505204. doi: 10.1155/2014/505204.

Castro RD, Lima ER. Anti-Candida activity and chemical composition of Cinnamomum zeylanicum blume essential oil. Braz Arch Biol Technol 2013; 56(5):749-55. doi: 10.1590/S1516-89132013000500005.

Ahmad A, Wani MY, Khan A, Manzoor N, Molepo J. Synergistic interactions of eugenol-tosylate and its congeners with fluconazole against Candida albicans. PLoS One 2015; 10(12):e0145053. doi: 10.1371/journal.pone.0145053.

Rosato A, Vitali C, Piarulli M, Mazzotta M, Argentieri MP, Mallamaci R. In vitro synergic efficacy of the combination of nystatin with the essential oils of Origanum vulgare and Pelargonium graveolens against some Candida species. Phytomedicine 2009; 16(10):972-5. doi: 10.1016/j.phymed.2009.02.011.

Pemmaraju SC, Pruthi PA, Prasad R, Pruthi V. Candida albicans biofilm inhibition by synergistic action of terpenes and fluconazole. Indian J Exp Biol 2013; 51(11):1032-7.

Doke SK, Raut JS, Dhawale S, Karuppayil SM. Sensitization of Candida albicans biofilms to fluconazole by terpenoids of plant origin. J Gen Appl Microbiol 2014; 60(5):163-8. doi: 10.2323/jgam.60.163.

Abrão PH, Pizi RB, de Souza TB, Silva NC, Fregnan AM, Silva FN, et al. Synthesis and biological evaluation of new eugenol mannich bases as promising antifungal agents. Chem Biol Drug Des 2015; 86(4):459-65. doi: 10.1111/cbdd.12504.

CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. CLSI Document M27-A3. 2008. Wayne, PA: CLSI.

Deswal DP, Chand U. Standardization of the tetrazolium test for viability estimation in rice bean (Vigna umbellata T.) seeds. Seed Sci Technol 1997; 25(3):409-17.

Pereira F de O, Mendes JM, Lima IO, Mota KS, Oliveira WA, Lima E de O. Antifungal activity of geraniol and citronellol, two monoterpenes alcohols, against Trichophyton rubrum involves inhibition of ergosterol biosynthesis. Pharm Biol 2015; 53(2):228-34. doi: 10.3109/13880209.2014.913299.

Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorian V (Ed.). Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins; 1991. p. 434-41.

Dutta NK, Dastidar SG, Kumar A, Mazumdar K, Ray R, Chakrabarty NA. Antimycobacterial activity of the anti-inflammatory agent sodium diclofenac, and its synergism with streptomycin. Braz J Microbiol 2004; 35(4):316-2. doi: 10.1590/S1517-83822004000300009.

Nightingale CH, Ambrose PG, Drusano GL, Murakawa T. Antimicrobial pharmacodynamics. In: Theory and clinical practice. 2.nd. ed. New York: Medical; 2002.

Ferreira GL, Pérez AL, Rocha ÍM, Pinheiro MA, de Castro RD, Carlo HL, et al. Does scientific evidence for the use of natural products in the treatment of oral candidiasis exist? A systematic review. Evid Based Complement Alternat Med 2015; 2015:147804. doi: 10.1155/2015/147804.

de Souza TB, de Oliveira Brito KM, Silva NC, Rocha RP, de Sousa GF, Duarte LP, et al. New eugenol glucoside-based derivative shows fungistatic and fungicidal activity against opportunistic Candida glabrata. Chem Biol Drug Des 2016; 87(1):83-90. doi: 10.1111/cbdd.12625.

Pramod K, Ansari SH, Ali J. Eugenol: a natural compound with versatile pharmacological actions. Nat Prod Commun 2010; 5(12):1999-2006.

Dabdoub SM, Tsigarida AA, Kumar PS. Patient-specific analysis of periodontal and peri-implant microbiomes. J Dent Res 2013; 92(12 Suppl):168S-75S. doi: 10.1177/0022034513504950.

Tanomaru-Filho M, Tanomaru JM, Barros DB, Watanabe E, Ito IY. In vitro antimicrobial activity of endodontic sealers, MTA-based cements and Portland cement. J Oral Sci 2007; 49(1):41-5. doi: 10.2334/josnusd.49.41.

Ahmad A, Khan A, Manzoor N, Khan LA. Evolution of ergosterol biosynthesis inhibitors as fungicidal against Candida. Microb Pathog 2010; 48(1):35 41. doi: 10.1016/j.micpath.2009.10.001.

Khan A, Ahmad A, Akhtar F, Yousuf S, Xess I, Khan LA, et al. Induction of oxidative stress as a possible mechanism of the antifungal action of three phenylpropanoids. FEMS Yeast Res 2011; 11(1):114-22. doi: 10.1111/j.1567-1364.2010.00697.x.

Carrasco H, Raimondi M, Svetaz L, Di Liberto M, Rodriguez MV, Espinoza L, et al. Antifungal activity of eugenol analogues. Influence of different substituents and studies on mechanism of action. Molecules 2012; 17(1):1002-24. doi: 10.3390/molecules17011002.


PBOCI is a member of CrossRef and all the content of its journals are linked by DOIs through CrossRef.